OncoCyte Corp (NYSEAMERICAN:OCX) major shareholder Broadwood Partners, L.P. bought 533,333 shares of the stock in a transaction on Friday, February 8th. The stock was purchased at an average price of $3.75 per share, for a total transaction of $1,999,998.75. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
OCX opened at $3.86 on Thursday. OncoCyte Corp has a 52-week low of $1.10 and a 52-week high of $6.92.
OncoCyte (NYSEAMERICAN:OCX) last released its quarterly earnings results on Tuesday, November 13th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.02.
OCX has been the topic of a number of recent research reports. initiated coverage on OncoCyte in a research note on Monday, October 29th. They issued a “positive” rating on the stock. Zacks Investment Research upgraded OncoCyte from a “hold” rating to a “buy” rating and set a $2.00 target price on the stock in a research note on Tuesday, November 20th. Lake Street Capital reiterated a “buy” rating on shares of OncoCyte in a research note on Wednesday, December 19th. Janney Montgomery Scott upgraded OncoCyte from a “neutral” rating to a “buy” rating in a research note on Tuesday, January 29th. Finally, Piper Jaffray Companies assumed coverage on OncoCyte in a research note on Wednesday. They set an “overweight” rating and a $6.00 price target for the company. One analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $5.50.
An institutional investor recently raised its position in OncoCyte stock. Vanguard Group Inc lifted its stake in shares of OncoCyte Corp (NYSEAMERICAN:OCX) by 3.8% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 410,275 shares of the biotechnology company’s stock after acquiring an additional 15,115 shares during the quarter. Vanguard Group Inc owned about 1.01% of OncoCyte worth $1,026,000 as of its most recent filing with the SEC.
COPYRIGHT VIOLATION NOTICE: This report was originally published by Macon Daily and is the sole property of of Macon Daily. If you are reading this report on another website, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The legal version of this report can be read at https://macondaily.com/2019/02/14/broadwood-partners-l-p-purchases-533333-shares-of-oncocyte-corp-ocx-stock.html.
OncoCyte Company Profile
OncoCyte Corporation focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer.
Further Reading: Why investors pay attention to retained earnings
Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.